Belimumab: A BLyS-Specific Inhibitor for the Treatment of Systemic Lupus Erythematosus
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference18 articles.
1. Pathogenesis of systemic lupus erythematosus
2. Systemic lupus erythematosus: modern strategies for management – a moving target
3. Current and novel therapeutics in the treatment of systemic lupus erythematosus
4. Systemic lupus erythematosus clinical trials—an interim analysis
5. Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Potential Opportunities of Modeling Bioavailability for Monoclonal Antibodies: An Overview of mAbs and the current challenges of mAb development;2024-04-18
2. Telitacicept Treatment Refractory Lupus Nephritis: A Case Report;Case Reports in Nephrology and Dialysis;2024-03-22
3. Impact of subcutaneous belimumab on disease activity, patient satisfaction, and metabolic profile in long-lasting systemic lupus erythematosus;Clinical Rheumatology;2024-02-09
4. Blockade of BLyS inhibits B-cell responses and antibody production for the prevention of chronic transplant rejection;The Journal of Heart and Lung Transplantation;2023-12
5. Co-Infection Talaromyces marneffei and Pneumocystis jirovecii in a Patient with Systemic Lupus Erythematosus;Infection and Drug Resistance;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3